Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company focused on ...

The 5th Circuit’s ruling on mifepristone “is bad for health care access, and it’s also bad for innovation,” writes Grace E.

When Daniel Haders, Ph.D., was working in venture capital, he was on the hunt for an AI-driven drug discovery company that ...

More than 200 drugs in the pipeline for ALS are stuck in a system that favors big, slow-moving pharmaceutical companies.

Biogen stock heads for its worst single-day drop since July 2024 on the heels of new clinical data.

The proceeds will be used to accelerate Isomorphic Labs’ pipeline of therapeutic programmes and further develop its IsoDDE AI ...

This week, the California Supreme Court is set to hear a case that could have far-reaching consequences for medical science.

NASA has enabled scientists to study the impact of microgravity on drug development for decades, beginning with the Space ...

Artificial intelligence has already made its mark in commercial industries, and there's a good argument to be made that AI is ...

Antibiotic resistance is a moving target, and even the most successful drugs eventually lose their edge. Around the turn of ...

There has been much discussion recently about how artificial intelligence and machine learning (AI/ML) will revolutionize pharmaceutical research. Substantial progress has been made in the discovery ...

From shrinking drug development timelines to scouting potential acquisitions, the recent run of first-quarter earnings results marked a shift for Big Pharma from AI hype to explaining how the ...